Daiwa Capital Markets America’s Vertex Pharmaceuticals VRTX Stock Holding History

Daiwa Capital Markets America’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$483K	Buy	+6,500	New	+$453K	﹤0.01%	387

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Daiwa Capital Markets America's VRTX Position: Q4 2013 in Review

Daiwa Capital Markets America opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2013: 6,500 shares worth $483K. The stake represents ﹤0.01% of the portfolio and ranks #387 among its holdings.

387 funds tracked by Wall St. Rank hold VRTX as of Q4 2013.

Daiwa Capital Markets America held 6,500 shares of Vertex Pharmaceuticals worth $483K as of Q4 2013.
Vertex Pharmaceuticals was a new Daiwa Capital Markets America position in Q4 2013.
Vertex Pharmaceuticals made up ﹤0.01% of Daiwa Capital Markets America's portfolio in Q4 2013, its #387 holding.
387 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2013.

Based on Daiwa Capital Markets America's 13F filing for Q4 2013, filed 13 Feb 2014.